Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Folate receptor-mediated tumor internal environment-sensitive doxorubicin albumin nanoparticles and preparation method

A technology of albumin nanoparticles and folic acid receptors, which can be used in antitumor drugs, medical preparations with non-active ingredients, and medical preparations containing active ingredients, etc. It can solve the problems of incomplete drug release and poor selectivity of nanoparticles. , to achieve the effect of achieving circulation stability, reducing drug toxicity and side effects, and increasing cellular uptake

Active Publication Date: 2022-04-15
SUZHOU UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Aiming at the problems of poor selectivity of existing chemotherapeutic drugs and incomplete release of traditional nanoparticle drugs, the present invention provides a drug with strong active targeting ability, high drug loading and embedding rate, complete drug release, and effective Folate receptor-mediated pH and reduction double-sensitive doxorubicin albumin nanoparticles for reducing toxic and side effects of drugs and preparation method thereof

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Folate receptor-mediated tumor internal environment-sensitive doxorubicin albumin nanoparticles and preparation method
  • Folate receptor-mediated tumor internal environment-sensitive doxorubicin albumin nanoparticles and preparation method
  • Folate receptor-mediated tumor internal environment-sensitive doxorubicin albumin nanoparticles and preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] This embodiment provides a folate receptor-mediated pH and reduction dual-sensitive doxorubicin albumin nanoparticles. See attached figure 1 , is a schematic diagram of the preparation process of folic acid receptor-mediated pH and reduction double-sensitive doxorubicin albumin nanoparticles, through aminocarboxyl condensation reaction and one-pot amide reaction, folic acid is grafted on the surface of bovine serum albumin successively and histamine, and then open the disulfide bond of the folic acid-albumin-histamine modifier through GSH, mix with the doxorubicin solution, and finally the disulfide bond spontaneously cross-links to form nanoparticles.

[0038] The specific preparation method of the present embodiment comprises the following steps:

[0039] 1. Synthesis of folic acid-albumin modifier:

[0040] Dissolve 88 mg folate acid (FA) in 4 mL dimethyl sulfoxide (DMSO), sonicate for 10 min, and add 58 mg 1-(3-dimethylaminopropyl)-3-ethyl carbon under stirring D...

Embodiment 2

[0050] This example investigates the particle size change of DOX / FBH-NPs prepared in Example 1 under the conditions of different pH and GSH concentration.

[0051] Filter the DOX / FBH-NPs with a 0.22 μM filter membrane, and sonicate for 5-10 minutes. The DOX / FBH-NPs solution was incubated in the following environments: phosphate buffered saline (PBS) at pH 7.4, PBS at pH 5.3, PBS at pH 7.4 and 10mM GSH, and the volume ratio of PBS to nanoparticle solution was 5: 1. The incubation time is 2 hours, the incubation temperature is 37°C, and then placed in a cuvette, put into the sample pool, and the particle size change is measured by a Malvern particle size analyzer. For the results, see the attached Image 6 ,Depend on Image 6 It can be seen that the particle size of DOX / FBH-NPs increases in PBS at pH 5.3, but the disulfide bonds of nanoparticles are opened under the condition of high concentration of GSH, and the particle size is disordered. This result proves that DOX / FBH-NPs...

Embodiment 3

[0053] In this example, the drug-loading behavior of DOX / FBH-NPs prepared in Example 1 was investigated.

[0054] Establish DOX standard curve equation 1: Accurately weigh an appropriate amount of DOX, use water as solvent, and dilute to the following concentrations: 100 μg / mL, 80 μg / mL, 40 μg / mL, 20 μg / mL, 10 μg / mL, 5 μg / mL, 2.5 μg / mL, 1.25 μg / mL, 0.625 μg / mL. The absorbance was measured with a multifunctional microplate reader. Do a linear regression with the DOX concentration on the absorbance value to obtain the standard curve equation: y=240.46x-11.213 (r 2 =0.9991).

[0055] The drug loading and encapsulation efficiency of DOX / FBH-NPs were calculated by formula (1) and formula (2), respectively.

[0056] The formula (1) for calculating the drug loading of DOX / FBH-NPs: the amount of drug loaded / the weight of the carrier; The difference in the amount of DOX in the serum.

[0057] The encapsulation efficiency calculation formula (2) of DOX / FBH-NPs: entrapped drug amoun...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a folic acid receptor-mediated tumor internal environment sensitive doxorubicin albumin nanoparticle and a preparation method. Condensation and acylation of amino and carboxyl groups to link folic acid to albumin; followed by a one-pot amide reaction to mix histamine with folic acid-albumin solution to obtain folic acid-albumin-histamine with folic acid targeting and pH sensitivity Modifier; use glutathione to open the disulfide bond inside folic acid-albumin-histamine, mix it with doxorubicin at alkaline pH, realize the spontaneous cross-linking of intermolecular disulfide bond, and obtain the folic acid receptor-mediated Guided pH- and glutathione-sensitive albumin doxorubicin nanoparticles. The nanoparticle provided by the present invention has a nearly spherical appearance and strong uniformity, a particle diameter of about 70nm, a small dispersion coefficient, good stability, and high drug loading and embedding efficiency of doxorubicin; The rapid release of drugs can be achieved under the dual stimulation of glutathione, which has important application value in the targeted delivery of drugs to tumors.

Description

technical field [0001] The invention relates to a folic acid receptor-mediated pH and reduction dual-sensitive albumin nano drug loading system and a preparation method thereof, belonging to the technical field of anti-tumor targeted drugs. Background technique [0002] Tumor has increasingly become a major killer that affects human health. A major problem with traditional chemotherapy drugs is the lack of targeting, which has great side effects on the body, and the amount of drugs that actually reach tumor cells and play a role is very small. Therefore, It is very important to design an effective and highly targeted drug delivery system. [0003] Due to their particle size and good surface properties, nanoparticles are easy to stay and accumulate in tumor tissues, so they are widely used in targeted drug delivery systems. Albumin is a good carrier for drug delivery in recent years, with many advantages and broad application prospects. In March 2016, the US FDA approved th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/54A61K47/64A61K47/69A61K31/704A61P35/00
CPCA61K47/545A61K47/643A61K47/6925A61P35/00A61K31/704
Inventor 张学农王丹丹陈维良
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com